Autologous Infusion of Bone Marrow and Mesenchymal Stromal Cells in Patients with Chronic Obstructive Pulmonary Disease: Phase I Randomized Clinical Trial.
Selma Denis SquassoniEliseo Joji SekiyaElie FissMonica Silveira LapaDaniela Dos Santos CayetanoFlávia NascimentoAdelson AlvesNadine Cristina MachadoBruna EscaramboniFrancislaine Aparecida Dos Reis LíveroMaria José Malagutti-FerreiraMurilo Racy SoaresFrancisco Winter Dos Santos FigueiredoBeatriz Kimberly Nath KramerPriscila Megda João Job ZagoJoão Tadeu Ribeiro-PaesPublished in: International journal of chronic obstructive pulmonary disease (2021)
The results obtained allow us to conclude that cell-based therapy with co-infusion of BMMC and ADSC is a safe procedure and a promising therapeutic for COPD. However, additional studies with a greater number of patients are needed before randomized and controlled Phase III clinical trials can be implemented.
Keyphrases
- phase iii
- bone marrow
- clinical trial
- double blind
- open label
- phase ii
- placebo controlled
- end stage renal disease
- low dose
- newly diagnosed
- cell therapy
- ejection fraction
- chronic kidney disease
- chronic obstructive pulmonary disease
- mesenchymal stem cells
- prognostic factors
- stem cells
- minimally invasive
- patient reported outcomes
- study protocol
- randomized controlled trial
- air pollution
- lung function
- replacement therapy